Early relapse of inflammatory breast carcinoma treated with lapatinib and capecitabine: Ten years of complete response

Breast J. 2020 Apr;26(4):800-802. doi: 10.1111/tbj.13606. Epub 2019 Sep 29.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Capecitabine / adverse effects
  • Female
  • Fluorouracil
  • Humans
  • Inflammatory Breast Neoplasms* / drug therapy
  • Lapatinib
  • Neoplasm Recurrence, Local / drug therapy
  • Receptor, ErbB-2
  • Trastuzumab
  • Treatment Outcome

Substances

  • Lapatinib
  • Capecitabine
  • Receptor, ErbB-2
  • Trastuzumab
  • Fluorouracil